Please assess the completion status of the following clinical trial:

Trial Title: 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed NSCLC, locally advanced and metastatic disease stage IIIB and IV. Evidence of disease progression after one or two cytotoxic treatment regimens which should have included a platinum agent.~2. Complete recovery from prior chemotherapy side effects to \< Grade 2.~3. At least one unidimensional measurable lesion meeting RECIST criteria.~4. ECOG PS 0-2.~5. Age \> 18 years.~6. Adequate organ function, including:~   * Adequate bone marrow reserve: ANC \> 1.5 x 109/L, platelets \> 100 x 109/L.~  * Hepatic: bilirubin \<1.5 x ULN, AP, ALT, AST \< 1.5 x ULN AP, ALT, and AST \<5 x ULN is acceptable if the liver has tumor involvement~  * Renal: calculated creatinin clearance \> 40 ml/min based on the Cockcroft-Gault formula.~7. Estimated life expectancy \>12 weeks.~8. Male and female patients with reproductive potential must use an approved contraceptive method, if appropriate. Female patients with childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment.~9. Signed informed consent.~10. Patient compliance and geographical proximity that allow adequate follow up.~Exclusion Criteria:~1. Pregnant or lactating women.~2. Patients with medical risks because of non-malignant disease as well as those with active uncontrolled infection.~3. Documented brain metastases unless the patient has completed local therapy for central nervous system metastases and has been off corticosteroids for at least two weeks before enrollment.~4. Previous treatment with an EGFR-TKI, or in non-squamous histology earlier treatment with pemetrexed and in squamous earlier treatment with docetaxel.~5. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (5 day period for long-acting agents such as piroxicam).~6. Inability or unwillingness to take folic acid, vitamin B-12 supplementation or dexamethasone.~7. Concomitant treatment with any other experimental drug under investigation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
- 2 (Type: ACTIVE_COMPARATOR): Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).